Company: CGCT
Filing Date: 2025-01-29
Form Type: S-1
Source: 0001104659-25-006780
Chunk: 81

Company: Cartesian Growth Corp III
Filing Date: 2025-01-29
Form: S-1
Chunk 81
---
 ultimately consummate a business combination, may be materially adversely affected by the continued effects of the coronavirus (COVID-19) pandemic and the status of debt and equity markets, as well as protectionist legislation in our target markets.

Since late 2019, the COVID-19 pandemic has
caused substantial disruption to global economies and markets and the virus has continued to spread on a global scale. A significant outbreak
of the COVID-19 and other infectious diseases, including the resurgence or variants thereof, could result in a widespread health
crisis that could adversely affect economies and financial markets worldwide, business operations and the conduct of commerce generally
and could have a material adverse effect on the business of any potential target business with which we complete a business combination.
Furthermore, we may be unable to complete a business combination if continued concerns relating to COVID-19 continue to restrict
travel, limit the ability to have meetings with potential investors or the target company’s personnel, vendors and services providers
are unavailable to negotiate and consummate a transaction in a timely manner or even to conduct requisite due diligence. In addition,
countries or supranational organizations in our target markets may develop and implement legislation that makes it more difficult or impossible
for entities outside such countries or target markets to acquire or otherwise invest in companies or businesses deemed essential or otherwise
vital. The extent to which COVID-19 impacts our search for a business combination will depend on future developments, which are highly
uncertain and cannot be predicted, including new information which may emerge concerning the severity and new variants of COVID-19 and
the actions to contain COVID-19 or treat its impact, among others. While vaccines for COVID-19 have been developed, there is
no guarantee that such vaccines will be durable. The treatment or vaccine for COVID-19 and any potentially emerging variants may
be ineffective or underutilized. If the disruptions posed by COVID-19 or other matters of global concern continue for an extensive
period of time, our ability to consummate a business combination, or the operations of a target business with which we ultimately consummate
a business combination, may be materially adversely affected. In addition, our ability to consummate a transaction may be dependent on
the ability to raise equity and debt financing which may be impacted by COVID-19 and other events, including as a result of increased
market volatility, decreased market liquidity and third-party financing being unavailable on terms acceptable to us or at all. Finally,
the outbreak of COVID-19 may also have the effect of heightening